Niall Ashfield investigates how cancer cells develop resistance to treatment. By recreating drug resistance in laboratory-grown cancer cells, his research examines the cellular changes that allow tumours to survive therapy. Identifying vulnerabilities in resistant cells could reveal alternative treatments, improve patient outcomes and support collaborations with pharmaceutical companies worldwide.
Aideen McCabe investigates earlier ovarian cancer detection through improved laboratory cell models and RNA-based biomarkers. Her research aims to identify suitable cell lines, discover potential diagnostic indicators and inform future treatments. Guided by patient partners, the project seeks to translate laboratory discoveries into clinical advances that improve patient outcomes.
This research develops pH-responsive biomaterials to deliver chemotherapy directly to glioblastoma cells in the brain. By releasing drugs in the presence of cancer while remaining closed around healthy tissue, the approach aims to improve treatment effectiveness, reduce harmful side effects, and ultimately enhance patients’ quality of life and survival.
This research investigates polyploid giant cancer cells, a highly treatment-resistant population responsible for cancer relapse. By studying their structural biology and dependence on lipid metabolism, the work identifies metabolic vulnerabilities that can be targeted alongside chemotherapy, offering a promising strategy to eliminate resistant cancer cells and improve long-term treatment outcomes.
This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.
This research engineers DNA-modified exosomes to deliver drugs precisely to cancer cells while avoiding healthy tissue. By disguising natural cell-targeting signals and adding programmable DNA targeting molecules, the platform could reduce treatment side effects and provide a modular delivery system adaptable to many cancers and other diseases.
This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.
This research develops gold nanoparticles coated with peptides to block DNA repair in colorectal cancer cells, helping overcome drug resistance. Laboratory studies show the treatment dramatically reduces cancer cell survival after radiation while minimising toxicity. The approach could provide a safer, more effective therapy for colorectal cancer and other drug-resistant cancers.
This research develops nanobubble-enhanced ultrasound imaging as an accessible alternative to MRI for cancer diagnosis. Tiny gas-filled nanoparticles amplify ultrasound signals and improve image quality, particularly in prostate cancer. The technology could reduce diagnostic delays, lower costs, and provide high-quality medical imaging to more patients worldwide.
This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.
Pagination
- Page 1
- Next page